Bio-Engineering tissue and V.A.C. therapy: A new method for the treatment of extensive necrotizing infection in the diabetic foot

Andrea Armenio, Daniela Anna Cutrignelli, Maria Luisa Nardulli, Giulio Maggio, Giuseppe Memeo, Valerio De Santis, Giuseppe Giudice, Cosmo Maurizio Ressa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

AIM: The aim of the study is to compare the standard care for progressive necrotizing infection in diabetic foot with a treatment protocol based on the association between autologous fibroblast grafts and vacuum-assisted closure therapy (V.A.C.). MATERIAL OF STUDY: A retrospective matched Case-Control study was carried out on 20 patients with diabetic foot infection, 10 treated with the standard care and 10 with our new protocol. Inclusion criteria were: acute diabetic foot necrosis (Wagner III and IV), ulcer size (30 to 80 cm2), tendon and bone exposure. Success in the treatment was evaluated as: percentage of healing at the 20th week, time of healing, deambulation, recurrence and major amputation rate. RESULTS: A 90% healing rate was observed after 20 weeks in the study group, compared to a 28.6% in the control group. The recurrence rate in the treated areas was 20% in the study group and 100% in the control group. None of the patients in either group required major amputations. DISCUSSION: We achieved very promising results by associating autologous fibroblasts grafts and V.A.C. therapy, in comparison with standard care. V.A.C. therapy seems to improve the growth rate of the fibroblasts, probably by sealing the wound and providing a moist environment following the fibroblast graft. The improved neoangiogenesis of the neo-dermis could explain the reduced recurrence rate of the study group. CONCLUSIONS: Despite the low number of patients involved and the retrospective nature of the analysis, this study showed a reliable, safe and cost-effective method of treating extensive infection in the diabetic foot.

Original languageEnglish
Pages (from-to)268-274
Number of pages7
JournalAnnali Italiani di Chirurgia
Volume88
Issue number3
Publication statusPublished - May 1 2017

Fingerprint

Negative-Pressure Wound Therapy
Bioengineering
Diabetic Foot
Fibroblasts
Infection
Transplants
Amputation
Recurrence
Therapeutics
Control Groups
Dermis
Clinical Protocols
Tendons
Ulcer
Case-Control Studies
Necrosis
Retrospective Studies
Costs and Cost Analysis
Bone and Bones
Wounds and Injuries

Keywords

  • Bio-Engineered Tissue
  • Diabetic foot
  • Fibroblast graft
  • V.A.C

ASJC Scopus subject areas

  • Surgery

Cite this

Bio-Engineering tissue and V.A.C. therapy : A new method for the treatment of extensive necrotizing infection in the diabetic foot. / Armenio, Andrea; Cutrignelli, Daniela Anna; Nardulli, Maria Luisa; Maggio, Giulio; Memeo, Giuseppe; De Santis, Valerio; Giudice, Giuseppe; Ressa, Cosmo Maurizio.

In: Annali Italiani di Chirurgia, Vol. 88, No. 3, 01.05.2017, p. 268-274.

Research output: Contribution to journalArticle

Armenio, Andrea ; Cutrignelli, Daniela Anna ; Nardulli, Maria Luisa ; Maggio, Giulio ; Memeo, Giuseppe ; De Santis, Valerio ; Giudice, Giuseppe ; Ressa, Cosmo Maurizio. / Bio-Engineering tissue and V.A.C. therapy : A new method for the treatment of extensive necrotizing infection in the diabetic foot. In: Annali Italiani di Chirurgia. 2017 ; Vol. 88, No. 3. pp. 268-274.
@article{82de36c0d38a452087562bbadb55bb94,
title = "Bio-Engineering tissue and V.A.C. therapy: A new method for the treatment of extensive necrotizing infection in the diabetic foot",
abstract = "AIM: The aim of the study is to compare the standard care for progressive necrotizing infection in diabetic foot with a treatment protocol based on the association between autologous fibroblast grafts and vacuum-assisted closure therapy (V.A.C.). MATERIAL OF STUDY: A retrospective matched Case-Control study was carried out on 20 patients with diabetic foot infection, 10 treated with the standard care and 10 with our new protocol. Inclusion criteria were: acute diabetic foot necrosis (Wagner III and IV), ulcer size (30 to 80 cm2), tendon and bone exposure. Success in the treatment was evaluated as: percentage of healing at the 20th week, time of healing, deambulation, recurrence and major amputation rate. RESULTS: A 90{\%} healing rate was observed after 20 weeks in the study group, compared to a 28.6{\%} in the control group. The recurrence rate in the treated areas was 20{\%} in the study group and 100{\%} in the control group. None of the patients in either group required major amputations. DISCUSSION: We achieved very promising results by associating autologous fibroblasts grafts and V.A.C. therapy, in comparison with standard care. V.A.C. therapy seems to improve the growth rate of the fibroblasts, probably by sealing the wound and providing a moist environment following the fibroblast graft. The improved neoangiogenesis of the neo-dermis could explain the reduced recurrence rate of the study group. CONCLUSIONS: Despite the low number of patients involved and the retrospective nature of the analysis, this study showed a reliable, safe and cost-effective method of treating extensive infection in the diabetic foot.",
keywords = "Bio-Engineered Tissue, Diabetic foot, Fibroblast graft, V.A.C",
author = "Andrea Armenio and Cutrignelli, {Daniela Anna} and Nardulli, {Maria Luisa} and Giulio Maggio and Giuseppe Memeo and {De Santis}, Valerio and Giuseppe Giudice and Ressa, {Cosmo Maurizio}",
year = "2017",
month = "5",
day = "1",
language = "English",
volume = "88",
pages = "268--274",
journal = "Annali Italiani di Chirurgia",
issn = "0003-469X",
publisher = "Edizioni Luigi Pozzi S.r.l.",
number = "3",

}

TY - JOUR

T1 - Bio-Engineering tissue and V.A.C. therapy

T2 - A new method for the treatment of extensive necrotizing infection in the diabetic foot

AU - Armenio, Andrea

AU - Cutrignelli, Daniela Anna

AU - Nardulli, Maria Luisa

AU - Maggio, Giulio

AU - Memeo, Giuseppe

AU - De Santis, Valerio

AU - Giudice, Giuseppe

AU - Ressa, Cosmo Maurizio

PY - 2017/5/1

Y1 - 2017/5/1

N2 - AIM: The aim of the study is to compare the standard care for progressive necrotizing infection in diabetic foot with a treatment protocol based on the association between autologous fibroblast grafts and vacuum-assisted closure therapy (V.A.C.). MATERIAL OF STUDY: A retrospective matched Case-Control study was carried out on 20 patients with diabetic foot infection, 10 treated with the standard care and 10 with our new protocol. Inclusion criteria were: acute diabetic foot necrosis (Wagner III and IV), ulcer size (30 to 80 cm2), tendon and bone exposure. Success in the treatment was evaluated as: percentage of healing at the 20th week, time of healing, deambulation, recurrence and major amputation rate. RESULTS: A 90% healing rate was observed after 20 weeks in the study group, compared to a 28.6% in the control group. The recurrence rate in the treated areas was 20% in the study group and 100% in the control group. None of the patients in either group required major amputations. DISCUSSION: We achieved very promising results by associating autologous fibroblasts grafts and V.A.C. therapy, in comparison with standard care. V.A.C. therapy seems to improve the growth rate of the fibroblasts, probably by sealing the wound and providing a moist environment following the fibroblast graft. The improved neoangiogenesis of the neo-dermis could explain the reduced recurrence rate of the study group. CONCLUSIONS: Despite the low number of patients involved and the retrospective nature of the analysis, this study showed a reliable, safe and cost-effective method of treating extensive infection in the diabetic foot.

AB - AIM: The aim of the study is to compare the standard care for progressive necrotizing infection in diabetic foot with a treatment protocol based on the association between autologous fibroblast grafts and vacuum-assisted closure therapy (V.A.C.). MATERIAL OF STUDY: A retrospective matched Case-Control study was carried out on 20 patients with diabetic foot infection, 10 treated with the standard care and 10 with our new protocol. Inclusion criteria were: acute diabetic foot necrosis (Wagner III and IV), ulcer size (30 to 80 cm2), tendon and bone exposure. Success in the treatment was evaluated as: percentage of healing at the 20th week, time of healing, deambulation, recurrence and major amputation rate. RESULTS: A 90% healing rate was observed after 20 weeks in the study group, compared to a 28.6% in the control group. The recurrence rate in the treated areas was 20% in the study group and 100% in the control group. None of the patients in either group required major amputations. DISCUSSION: We achieved very promising results by associating autologous fibroblasts grafts and V.A.C. therapy, in comparison with standard care. V.A.C. therapy seems to improve the growth rate of the fibroblasts, probably by sealing the wound and providing a moist environment following the fibroblast graft. The improved neoangiogenesis of the neo-dermis could explain the reduced recurrence rate of the study group. CONCLUSIONS: Despite the low number of patients involved and the retrospective nature of the analysis, this study showed a reliable, safe and cost-effective method of treating extensive infection in the diabetic foot.

KW - Bio-Engineered Tissue

KW - Diabetic foot

KW - Fibroblast graft

KW - V.A.C

UR - http://www.scopus.com/inward/record.url?scp=85030536652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030536652&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85030536652

VL - 88

SP - 268

EP - 274

JO - Annali Italiani di Chirurgia

JF - Annali Italiani di Chirurgia

SN - 0003-469X

IS - 3

ER -